CRISPR Therapeutics AG

Equities

CRSP

CH0334081137

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
71.47 USD -2.03% Intraday chart for CRISPR Therapeutics AG -6.96% +14.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Mizuho Adjusts Price Target on CRISPR Therapeutics to $99 From $82, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on CRISPR Therapeutics to $48 From $46, Maintains Underweight Rating MT
Wells Fargo Raises Price Target on CRISPR Therapeutics to $70 From $55, Maintains Equal-Weight Rating MT
Barclays Raises Price Target on CRISPR Therapeutics to $80 From $61, Maintains Equal-Weight Rating MT
Chardan Ups Price Target on CRISPR Therapeutics to $112 From $110, Keeps Buy Rating MT
RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept MT
Transcript : CRISPR Therapeutics AG Presents at Citi 2024 Virtual Oncology Leadership Summit, Feb-21-2024 10:00 AM
Needham Adjusts CRISPR Therapeutics' Price Target to $90 From $88, Keeps Buy Rating MT
CRISPR Therapeutics Swings to Q4 Profit, Revenue Increases MT
CRISPR Therapeutics AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Reports Q4 Revenue $201.2M MT
Earnings Flash (CRSP) CRISPR THERAPEUTICS AG Posts Q4 EPS $1.10 MT
CRISPR Therapeutics AG Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Crispr Therapeutics Ag Insider Sold Shares Worth $1,607,177, According to a Recent SEC Filing MT
Wolfe Research Starts Coverage on CRISPR Therapeutics With Peer Perform Rating MT
CRISPR Therapeutics to Sell About $280 Million of Common Shares MT
CRISPR Therapeutics Secures Conditional Marketing Approval in Europe for Casgevy to Treat Sickle Cell Disease, Transfusion-Dependent Beta Thalassemia MT
European Commission Grants Crispr Therapeutics Conditional Marketing Permit for Casgevy MT
Crispr Therapeutics Announces European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY? CI
CRISPR Therapeutics Gets FDA Approval For Casgevy to Treat Transfusion-Dependent Beta Thalassemia MT
CRISPR Therapeutics Announces U.S. Food and Drug Administration Approval of CASGEVY? for the Treatment of Transfusion-Dependent Beta Thalassemia CI
US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder RE
Transcript : CRISPR Therapeutics AG Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery RE
Kempen Downgrades CRISPR Therapeutics to Neutral From Buy, Cuts Price Target to $65 From $80 MT
Chart CRISPR Therapeutics AG
More charts
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
71.47 USD
Average target price
88 USD
Spread / Average Target
+23.13%
Consensus
  1. Stock
  2. Equities
  3. Stock CRISPR Therapeutics AG - Nasdaq
  4. News CRISPR Therapeutics AG
  5. CRISPR Therapeutics : Citigroup Lifts CRISPR Therapeutics to Neutral From Sell, Price Target to $132 From $55